Retatrutide FDA Approval Timeline: What to Watch in 2026-2027

Tracking the retatrutide FDA approval process — key milestones, expected dates, and what could delay approval.

Current Regulatory Status

Retatrutide is in Phase 3 clinical trials under Eli Lilly's development program. The TRIUMPH-1 and TRIUMPH-4 trials are the primary efficacy studies, with readouts expected to support a New Drug Application (NDA) filing. The expected timeline puts FDA approval potentially in 2027, assuming positive Phase 3 results and no major safety findings.

The FDA has granted retatrutide fast track designation, which could accelerate the review timeline.

Key Milestones to Watch

Phase 3 top-line data readout, NDA submission, FDA acceptance for review, Advisory Committee meeting, and PDUFA date. Each milestone affects both clinical access and compounding availability.

📊 Dosage Calculator & Protocol Chart

Use our free Retatrutide dosage calculator to plan your protocol:

👉 Retatrutide Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.

👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.

Important Disclaimer

This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: retatrutide, weight loss, GLP-1, phase 3, triple agonist

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content